151,474 Shares in Xenon Pharmaceuticals Inc. $XENE Bought by Hsbc Holdings PLC

Hsbc Holdings PLC bought a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 151,474 shares of the biopharmaceutical company’s stock, valued at approximately $9,143,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Castleark Management LLC purchased a new position in shares of Xenon Pharmaceuticals in the 2nd quarter valued at about $3,728,000. Nicholas Investment Partners LP acquired a new position in Xenon Pharmaceuticals in the second quarter valued at approximately $23,893,000. Parkman Healthcare Partners LLC acquired a new position in Xenon Pharmaceuticals in the second quarter valued at approximately $23,986,000. Legal & General Group Plc purchased a new position in Xenon Pharmaceuticals in the second quarter valued at approximately $4,450,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Xenon Pharmaceuticals during the second quarter worth approximately $1,746,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Trading Down 3.1%

Shares of XENE stock opened at $59.99 on Friday. The business’s 50 day moving average is $63.18 and its two-hundred day moving average is $56.39. Xenon Pharmaceuticals Inc. has a twelve month low of $35.60 and a twelve month high of $72.66. The company has a market capitalization of $5.80 billion, a P/E ratio of -12.66 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same period in the previous year, the firm posted ($1.07) EPS. As a group, equities analysts predict that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

XENE has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. HC Wainwright restated a “buy” rating and issued a $74.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday, August 10th. Royal Bank Of Canada dropped their price objective on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. JPMorgan Chase & Co. lifted their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 27th. Finally, Needham & Company LLC reduced their target price on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of “Buy” and an average target price of $77.13.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the transaction, the director directly owned 24,896 shares of the company’s stock, valued at approximately $1,322,973.44. The trade was a 5.04% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. The trade was a 44.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 12,512 shares of company stock valued at $774,088. 2.91% of the stock is owned by company insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.